Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Shrader

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Diabetes Care|October 5, 2010
Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphismsJose M de Miguel-Yanes, Peter Shrader, Michael J Pencina, et al.
Pediatric Cardiology|November 23, 2013
The relationship of patient medical and laboratory characteristics to changes in functional health status in children and adolescents after the Fontan procedureBrian W McCrindle, Victor Zak, Roger E Breitbart, et al.
American Journal of Preventive Cardiology|January 29, 2025
Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registrySatoshi Shoji, Nishant P Shah, Peter Shrader, et al.
Journal of the American College of Cardiology|December 17, 2016
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II RegistryBenjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Journal of the American College of Cardiology|September 9, 2017
Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF RegistryJustin B Echouffo-Tcheugui, Peter Shrader, Laine Thomas, et al.
The Journal of Pediatrics|December 20, 2015
Assessment of Quality of Life in Young Patients with Single Ventricle after the Fontan OperationKaren Uzark, Victor Zak, Peter Shrader, et al.
Circulation. Heart Failure|October 18, 2013
Predictors of disease progression in pediatric dilated cardiomyopathyKimberly M Molina, Peter Shrader, Steven D Colan, et al.
American Heart Journal|June 20, 2017
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Circulation|October 19, 2016
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product LabelingSean D Pokorney, Peter Shrader, Laine Thomas, et al.
JACC. Clinical Electrophysiology|May 17, 2018
Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF RegistryAmit Noheria, Peter Shrader, Jonathan P Piccini, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Diabetes Care|October 5, 2010
Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphismsJose M de Miguel-Yanes, Peter Shrader, Michael J Pencina, et al.
Pediatric Cardiology|November 23, 2013
The relationship of patient medical and laboratory characteristics to changes in functional health status in children and adolescents after the Fontan procedureBrian W McCrindle, Victor Zak, Roger E Breitbart, et al.
American Journal of Preventive Cardiology|January 29, 2025
Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registrySatoshi Shoji, Nishant P Shah, Peter Shrader, et al.
Journal of the American College of Cardiology|December 17, 2016
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II RegistryBenjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Journal of the American College of Cardiology|September 9, 2017
Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF RegistryJustin B Echouffo-Tcheugui, Peter Shrader, Laine Thomas, et al.
The Journal of Pediatrics|December 20, 2015
Assessment of Quality of Life in Young Patients with Single Ventricle after the Fontan OperationKaren Uzark, Victor Zak, Peter Shrader, et al.
Circulation. Heart Failure|October 18, 2013
Predictors of disease progression in pediatric dilated cardiomyopathyKimberly M Molina, Peter Shrader, Steven D Colan, et al.
American Heart Journal|June 20, 2017
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)Benjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Circulation|October 19, 2016
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product LabelingSean D Pokorney, Peter Shrader, Laine Thomas, et al.
JACC. Clinical Electrophysiology|May 17, 2018
Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF RegistryAmit Noheria, Peter Shrader, Jonathan P Piccini, et al.
Pageof 9